Main Uses of Finasteride

Finasteride is a pharmacological treatment primarily indicated for two distinct conditions influenced by androgenic hormones. It belongs to a class of medications known as 5-alpha reductase inhibitors, which work by blocking the conversion of testosterone into dihydrotestosterone (DHT).

Male Pattern Hair Loss (Androgenetic Alopecia)

One of the primary uses of finasteride is the treatment of androgenetic alopecia in men. This condition is characterized by the progressive thinning of hair on the scalp, often following a specific pattern such as a receding hairline or thinning at the crown.

In the scalp, DHT contributes to the miniaturization of hair follicles, leading to shorter, thinner hairs and eventually the cessation of hair growth. By reducing systemic and local levels of DHT, finasteride helps to:

• Slow hair loss: Many individuals experience a significant reduction in the rate of hair shedding.
• Promote regrowth: Some users may notice an increase in hair count and improved coverage in previously thinning areas.
• Improve hair quality: Existing hair may become thicker and stronger over time.

Benign Prostatic Hyperplasia (BPH)

Finasteride is also used to treat symptoms associated with an enlarged prostate, a condition known as benign prostatic hyperplasia. BPH is common in aging men and occurs when the prostate gland grows in size, potentially compressing the urethra and causing urinary difficulties.

Because prostate growth is heavily dependent on DHT, lowering the levels of this hormone can lead to a reduction in the volume of the prostate gland. The benefits of treatment in this context include:

• Improvement in urinary flow: Reducing the size of the gland eases the pressure on the urethra.
• Reduction of urinary symptoms: This includes a decrease in the frequency of urination, less nighttime waking (nocturia), and a reduction in the sensation of incomplete bladder emptying.
• Lower risk of acute complications: Long-term treatment can reduce the likelihood of sudden urinary retention or the need for prostate-related surgery.

Therapeutic Benefits

The clinical objective of using finasteride is to manage the underlying hormonal factors contributing to these conditions. While the medication does not provide a permanent cure, it offers a consistent method for controlling symptoms and slowing the progression of both hair loss and prostate enlargement as long as the treatment is maintained.

Regulatory References

1. MedlinePlus Drug Information

Finasteride's regulatory eligibility is strictly defined, limiting use to adult men. Its use is formally contraindicated and not indicated for several populations, as documented in official prescribing information from authorities like the FDA and EMA.

---

Populations Not Eligible for Use

Classification	Population	Status Based on Regulatory Documents
Contraindicated	Females who are pregnant or may potentially be pregnant	Absolute prohibition due to risk of external genitalia abnormalities in a male fetus.
Contraindicated	Patients with known Hypersensitivity	Prohibition due to allergy to finasteride or formulation components.
Not Indicated	Females/Women	The drug is exclusively approved for use in men.
Not Indicated	Pediatric Patients (under 18 years)	Safety and effectiveness have not been established in this age group.

---

Conditional Use and Special Populations

Condition	Regulatory Stipulation
Hepatic Impairment	Caution is advised because the drug is extensively metabolized in the liver.
Renal Impairment	No dosage adjustment is necessary for patients with varying degrees of chronic renal insufficiency.
Tablets	Females who are pregnant or may potentially be pregnant must not handle crushed or broken tablets due to potential skin absorption.

Finasteride’s interaction profile is characterized by its minimal effect on co-administered medicinal products. Official regulatory documents consistently state that no drug interactions of clinical importance have been identified.

Drug–Drug Interactions

The medication does not appear to significantly influence the Cytochrome P450-linked drug metabolizing enzyme system. This finding serves as the basis for the conclusion that finasteride is unlikely to alter the exposure or clearance of other drugs through this common metabolic pathway. Compounds that have been formally tested in human studies and found to have no clinically meaningful interactions include:

• Digoxin
• Propranolol
• Theophylline
• Warfarin
• Glibenclamide

While finasteride is primarily metabolized via the CYP3A4 enzyme, co-administration with known inhibitors or inducers of this enzyme is officially considered unlikely to be of clinical significance regarding finasteride's plasma concentration.

Food and Administration Restrictions

The official regulatory profile confirms that the bioavailability of finasteride is not affected by food. Therefore, administration may occur with or without meals, and no mandatory timing separation rules are documented in the core regulatory labels. Furthermore, no drug-drug combinations involving finasteride are formally classified as contraindicated due to an interaction risk.

Population-Specific Notes

Official documents state that no dosage adjustment is required for patients with renal impairment, as studies showed no change in the disposition of finasteride in this population.

Mechanism of Action: Enzymatic Inhibition

Finasteride functions as a specific, competitive inhibitor of the 5-alpha reductase enzyme, acting predominantly on the Type II isoform found in peripheral tissues like the prostate and scalp hair follicles. By binding tightly to this enzyme, the drug blocks the critical metabolic step that converts the androgen testosterone into the more potent hormone, Dihydrotestosterone (DHT). This specific enzymatic blockade alters the androgen metabolic pathway.

The inhibition rapidly leads to a sustained reduction in both circulating serum DHT and local tissue DHT concentrations. This reduction diminishes the stimulatory signal DHT provides to androgen receptors within sensitive cells. The resulting downstream cellular effects include a decrease in DHT-driven processes, leading to a change in the cellular morphology and activity that reflects decreased androgenic stimulation.

The maximal observable physiological consequence is inherently slow, requiring continuous DHT suppression over several months, which allows for the slow turnover and structural remodeling of the affected hormone-sensitive tissues. The Type I isoform is inhibited to a lesser extent, defining the boundaries of the mechanism's inhibitory effect.

Official Administration Instructions

Finasteride is an oral medication taken once daily. The specific dose is determined by the condition being addressed.

Dosage Context	Daily Dose	Administration Method
Benign Prostatic Hyperplasia (BPH)	One 5 mg tablet	Swallow whole
Male Pattern Hair Loss	One 1 mg tablet	Swallow whole

Route and Timing:

The route of administration is Oral. The medication can be taken with or without food. The tablet is generally taken at approximately the same time each day.

Preparation and Handling Restrictions:

Finasteride tablets must be swallowed whole and should not be crushed, broken, or chewed. This administration step ensures proper dosing and maintains the integrity of the film coating.

Crucially, pregnant women or women who may potentially be pregnant must not handle crushed or broken finasteride tablets. This specialized handling instruction exists due to the potential for absorption of the active ingredient through the skin, presenting a risk to a male fetus.

Instructions for Missed Doses:

If a dose is missed, the instruction is to skip the missed dose and continue with the regular daily schedule. A double dose should not be taken to compensate for the missed dose.

Research Evidence / Overview of Studies for Finasteride

---

Evidence for Use in Benign Prostatic Hyperplasia (BPH)

Research has widely explored Finasteride for men with conditions characterized by functional limitations related to an enlarged prostate. It was studied for outcomes related to physical discomfort in the lower urinary tract. Studies were generally used in research exploring how symptoms change over time and applied in studies examining patient-reported experiences related to urinary flow and frequency. Research examined how symptoms evolved in the observed populations, and findings describe patterns observed in the studies, examining how outcomes related to systemic or functional imbalance evolved in the observed populations.

The main body of evidence comes from large clinical trials conducted over several years. The evidence contributes to understanding symptom patterns, and some research highlights changes measured during the study period associated with managing conditions involving periods of heightened symptoms.

---

Evidence for Use in Male-Pattern Hair Loss (Androgenetic Alopecia)

Finasteride was also studied for use in men experiencing male-pattern hair loss. The research exploring this condition focused on outcomes related to systemic or functional imbalance linked to hair follicles. These studies were relevant in trials assessing short-term or episodic symptom patterns, primarily over one to two years.

Studies explored changes measured during the study period related to patient-reported outcomes describing perceived discomfort. Data show patterns related to outcomes reflecting daily functioning or activity level in some individuals observed in the studies. The findings help contextualize how patients reported their experience and how that was associated with the treatment duration.

---

What is Still Uncertain About Finasteride

The evidence highlights what is known, but also where gaps exist in the research for Finasteride. For example, comparative evidence is lacking when assessing Finasteride against every other available treatment option for both indications. Research has evaluated short-term symptom changes for hair loss, but the information for long-term outcomes for this indication remains insufficient. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

1. NICE Final Scope: Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (includes Finasteride in background guidance)

Common questions about Finasterida (FAQ)

---

Q: What is Finasterida and how does it work?

A: Finasterida is a medication used to treat male pattern baldness (androgenetic alopecia) and benign prostatic hyperplasia (BPH, or an enlarged prostate).

It works by blocking an enzyme called 5-alpha reductase. This enzyme is responsible for converting the male hormone testosterone into a more potent hormone called dihydrotestosterone (DHT). By lowering DHT levels, Finasterida helps slow, halt, or potentially reverse hair loss and can reduce the size of the prostate in BPH.

---

Q: What results can I expect and how long does Finasterida take to work for hair loss?

A: Clinical studies show Finasterida is effective for treating male pattern baldness, especially in men with mild to moderate hair loss at the crown and hairline. The medication helps preserve existing hair and can promote regrowth.

Results are not immediate and require consistent, long-term use. It typically takes at least 6 to 12 months of daily use before any visible effects, such as a halt in hair loss or hair regrowth, become noticeable.

---

Q: What are the most common side effects of Finasterida?

A: Like all medications, Finasterida can cause side effects. The most common reported side effects are related to sexual function, which may include:

• Decreased sex drive (libido)
• Difficulty getting or keeping an erection (erectile dysfunction)
• Decrease in the amount of semen during ejaculation

Other potential side effects include breast tenderness or enlargement (gynecomastia) and mood changes, such as depressed mood, depression, or even suicidal thoughts. Some men have reported these sexual side effects or mood changes persisting after stopping the medication.

---

Q: Can Finasterida be used by women?

A: No, Finasterida is not recommended for use in women. It is especially important for women who are pregnant or may become pregnant to avoid handling crushed or broken Finasterida tablets, as the medication can be absorbed through the skin and may cause birth defects in a developing male fetus. The medication is only approved for use in men for male pattern hair loss and BPH.

---

Q: Does Finasterida affect the Prostate Specific Antigen (PSA) test result?

A: Yes, Finasterida can affect the result of the Prostate Specific Antigen (PSA) test, which is a blood test often used to screen for prostate cancer. Finasterida typically lowers PSA levels by about 50% after a few months of treatment.

It is important to tell your doctor if you are taking Finasterida before having a PSA test, as they will need to use a modified baseline to accurately interpret your results.

---

Q: Does Finasterida increase the risk of prostate cancer?

A: Finasterida has been shown to reduce the overall risk of prostate cancer when used for benign prostatic hyperplasia (BPH). However, some studies have noted a potential for a higher detection rate of high-grade prostate cancer (a more aggressive type) in men taking Finasterida.

This finding is complex and may be due, in part, to the drug making it easier for doctors to detect cancer by improving the sensitivity of the PSA test. The potential benefits of Finasterida for BPH and cancer prevention must be weighed against this risk and the risk of sexual side effects. Your doctor is the best source for discussing these risks.

Finasteride tablets must be stored at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F), and kept away from excessive heat and moisture. The tablets must remain in the original container, which should be tightly closed to maintain product stability and be stored in a dry place, protected from light.

Handling and Child Safety

Finasteride tablets are coated, but pregnant or potentially pregnant women must not handle crushed or broken tablets due to the potential risk of absorption. The medication must be kept strictly out of the sight and reach of children.

Disposal

Unused or expired finasteride should be disposed of through an authorized drug take-back program. If a program is not available, the product must be discarded in a manner consistent with local regulatory waste instructions and should not be flushed down a toilet or poured down a drain.